Literature DB >> 1678965

Hemodynamic evaluation of bisoprolol after coronary artery surgery in patients with altered left ventricular function.

M Goldstein1, J L Vincent, J L Le Clerc, A d'Hollander, C Melot, R J Kahn.   

Abstract

Bisoprolol is a new cardioselective beta1 adrenergic blocking agent without intrinsic sympathomimetic activity but with minimal effects on myocardial contractility. Bisoprolol was compared to propranolol in 24 patients after cardiac surgery for coronary artery bypass graft (CABG). Each patient had been treated preoperatively with beta-blocking agents and had a cineangiographic left ventricular ejection fraction between 35% and 55%. Patients were randomized to receive orally either 10 mg of propranolol three times a day or 5 mg of bisoprolol once a day. Both drugs resulted in a significant and similar decrease in heart rate. This was associated with significant decreases in cardiac index, stroke index, and thermodilution right ventricular ejection fraction 6 hours after administration of propranolol, but not after bisoprolol. Systolic function measured by Doppler techniques significantly increased in the 10 postoperative days in patients under bisoprolol but not significantly after propranolol. Each drug was well tolerated during the 10 postoperative days, and the recovery was uneventful in each patient. These results indicate that in patients with altered systolic function after CABG, bisoprolol is susceptible to reduce heart rate with less cardiovascular alteration than propranolol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678965     DOI: 10.1007/bf03029731

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  27 in total

1.  Summary of short- and long-term studies with bisoprolol in coronary heart disease (CHD).

Authors:  G Wagner
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

2.  Effect of bisoprolol on exercise tolerance in patients with coronary heart disease: placebo-controlled double-blind crossover study.

Authors:  K Schnellbacher; E Marsovszky; H Roskamm
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

3.  Evolution of right ventricular performance after CABG.

Authors:  O Bastien; P G Durand; M George; A Gurbala; S Estanove
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

4.  Thermodilution measurement of right ventricular ejection fraction with a modified pulmonary artery catheter.

Authors:  J L Vincent; M Thirion; S Brimioulle; P Lejeune; R J Kahn
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

5.  Evaluation of cardiac function by echo-Doppler studies in critically ill patients.

Authors:  M Goldstein; J L Vincent; R J Kahn
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

6.  Effects on right ventricular function of a change from dopamine to dobutamine in critically ill patients.

Authors:  J L Vincent; C Reuse; R J Kahn
Journal:  Crit Care Med       Date:  1988-07       Impact factor: 7.598

7.  Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol.

Authors:  J Harting; K H Becker; R Bergmann; R Bourgois; H J Enenkel; A Fuchs; R Jonas; H Lettenbaur; K O Minck; P Schelling
Journal:  Arzneimittelforschung       Date:  1986-02

8.  Noninvasive assessment of left ventricular performance after administration of bisoprolol.

Authors:  R J Esper; R C Esper; O H Burrieza; J Menna
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

9.  Effects of bisoprolol in relation to metoprolol and bufuralol on left ventricular hemodynamics at rest and during exercise in chronic ischemic heart disease.

Authors:  F Burkart; M Pfisterer; E Steinmann
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

10.  Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients.

Authors:  J W Lammers; H T Folgering; C L van Herwaarden
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.